Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications

Phase II and phase III failures: 2013–2015

(2016) Richard K. Harrison   NATURE REVIEWS DRUG DISCOVERY

Trends in clinical success rates

(2016) Katarzyna Smietana et al.   NATURE REVIEWS DRUG DISCOVERY

A comprehensive map of molecular drug targets

(2016) Rita Santos et al.   NATURE REVIEWS DRUG DISCOVERY

Solanezumab and the amyloid hypothesis for Alzheimer’s disease

(2016) David G Le Couteur et al.   BMJ-British Medical Journal

Solanezumab and the amyloid hypothesis for Alzheimer’s disease

(2016) David G Le Couteur et al.   BMJ-British Medical Journal

Toxicology Strategies for Drug Discovery: Present and Future

(2015) Eric A. G. Blomme et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

(2015) Andreas Soejitno et al.   CNS DRUGS

Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use

(2015) Guido Antonelli et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future

(2015) Ling-Jun Ho et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Animal models of rheumatoid arthritis: How informative are they?

(2015) Kay McNamee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Targeting cancer with kinase inhibitors

(2015) Stefan Gross et al.   JOURNAL OF CLINICAL INVESTIGATION

The support of human genetic evidence for approved drug indications

(2015) Matthew R Nelson et al.   NATURE GENETICS

Translational value of mouse models in oncology drug development

(2015) Stephen E Gould et al.   NATURE MEDICINE

Why is it hard to terminate failing projects in pharmaceutical R&D?

(2015) Richard W. Peck et al.   NATURE REVIEWS DRUG DISCOVERY

An analysis of the attrition of drug candidates from four major pharmaceutical companies

(2015) Michael J. Waring et al.   NATURE REVIEWS DRUG DISCOVERY

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

(2014) Helen King et al.   CANCER TREATMENT REVIEWS

Addressing toxicity risk when designing and selecting compounds in early drug discovery

(2014) Matthew D. Segall et al.   DRUG DISCOVERY TODAY

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

(2014) Ivan Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Improving and Accelerating Drug Development for Nervous System Disorders

(2014) Diana E. Pankevich et al.   NEURON

TNF inhibitors – Mechanisms of action, approved and off-label indications

(2014) Grzegorz Cessak et al.   Pharmacological Reports

The therapeutics of Alzheimer's disease: Where we stand and where we are heading

(2013) Dennis J. Selkoe   ANNALS OF NEUROLOGY

Animal models of CNS disorders

(2013) Paul McGonigle   BIOCHEMICAL PHARMACOLOGY

Recent failures in antiatherosclerotic drug development

(2013) Robert M. Stoekenbroek et al.   CURRENT OPINION IN LIPIDOLOGY

Targeting leukotriene B4in inflammation

(2013) Antonio Di Gennaro et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

ACAT Inhibitors: The Search for Novel Cholesterol Lowering Agents

(2013) Palash Pal et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Does size matter in R&D productivity? If not, what does?

(2013) Michael Ringel et al.   NATURE REVIEWS DRUG DISCOVERY

Novelty in the target landscape of the pharmaceutical industry

(2013) Pankaj Agarwal et al.   NATURE REVIEWS DRUG DISCOVERY

Phase II and Phase III attrition rates 2011–2012

(2013) John Arrowsmith et al.   NATURE REVIEWS DRUG DISCOVERY

Validating therapeutic targets through human genetics

(2013) Robert M. Plenge et al.   NATURE REVIEWS DRUG DISCOVERY

Orphan drug development: an economically viable strategy for biopharma R&D

(2012) Kiran N. Meekings et al.   DRUG DISCOVERY TODAY

Aliskiren, the first direct renin inhibitor for treatment of hypertension: The path of its development

(2012) M Jadhav et al.   Journal of Postgraduate Medicine

Rare diseases and orphan drugs

(2012) Irena Melnikova   NATURE REVIEWS DRUG DISCOVERY

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

(2012) Joanne Bowes et al.   NATURE REVIEWS DRUG DISCOVERY

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Getting pharmaceutical R&D back on target

(2011) Mark E Bunnage   Nature Chemical Biology

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Phase II failures: 2008–2010

(2011) John Arrowsmith   NATURE REVIEWS DRUG DISCOVERY

The productivity crisis in pharmaceutical R&D

(2011) Fabio Pammolli et al.   NATURE REVIEWS DRUG DISCOVERY

Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

(2010) J A DiMasi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

5-Lipoxygenase inhibitors: a review of recent developments and patents

(2010) Carlo Pergola et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Anticancer drug development: the grand challenges

(2010) William N. Hait   NATURE REVIEWS DRUG DISCOVERY

Modelling and PBPK Simulation in Drug Discovery

(2009) Hannah M. Jones et al.   AAPS Journal

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

(2009) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies

(2009) Nemanja Damjanov et al.   ARTHRITIS AND RHEUMATISM

Comprehensive Assessment of ADMET Risks in Drug Discovery

(2009) Jianling Wang   CURRENT PHARMACEUTICAL DESIGN

ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia

(2009) Marijn C. Meuwese et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Aliskiren: the first renin inhibitor for clinical treatment

(2008) Chris Jensen et al.   NATURE REVIEWS DRUG DISCOVERY

Muscarinic acetylcholine receptors as CNS drug targets

(2007) Christopher J. Langmead et al.   PHARMACOLOGY & THERAPEUTICS